What if the first warning sign of Alzheimer’s disease was already sitting in a blood test that millions of people take every year — and nobody was looking at it?
A major study from NYU Langone Health, analyzing data from nearly 400,000 patients across two healthcare systems, has found that an elevated neutrophil-to-lymphocyte ratio (NLR) — a simple inflammation marker derived from a standard complete blood count — is associated with a significantly increased risk of developing Alzheimer’s disease and related dementias years before any cognitive symptoms appear.
The Immune Clock
Neutrophils are the body’s first responders — white blood cells that rush to sites of infection and injury. The NLR compares their count against lymphocytes, another class of immune cells. A higher ratio indicates chronic, systemic inflammation.
What the NYU researchers discovered is that this elevation is happening before any evidence of cognitive decline. Patients with persistently high NLR values were more likely to develop dementia in subsequent years, even when they showed no memory problems at the time of the blood test.
The finding, published April 3 in the journal Alzheimer’s & Dementia, raises a critical question: are neutrophils merely reflecting an inflammatory process already underway in the brain, or are they actively contributing to the disease’s progression?
Who Is Most at Risk
The predictive power of the NLR was not uniform across populations. Women showed a higher correlation between elevated NLR and future cognitive decline. Hispanic patients faced a disproportionately higher risk linked to these values. These demographic patterns suggest that inflammation-driven dementia risk may interact with hormonal, genetic, or environmental factors in ways that are not yet fully understood.
A Test That Already Exists
Perhaps the most striking aspect of this discovery is that the test is already in routine use. Complete blood counts are among the most commonly ordered laboratory tests in medicine. The NLR can be calculated from results that already exist in millions of patient records — no new technology, no expensive biomarker panels, no specialized imaging required.
The data has been there all along. The question is whether clinicians will now begin to use it — and whether patients flagged early can be offered interventions that slow or prevent the disease before it steals their memory.
